Discover your next big idea for life sciences at PACK EXPO Las Vegas
Experience a breakthrough in life sciences packaging—explore solutions from 2,300 suppliers spanning all industries, all in one place this September

Reporting Suspicious Orders to the DEA

A DEA Diversion Program Manager highlighted controlled substance order reporting and paperwork to keep on-hand.

At this week’s Pharma & Device Packaging & Labeling West Coast educational conference in Burlingame, CA, DEA’s Stephen Buzzeo noted that manufacturers of controlled substances are required to report suspicious ordering to the DEA. 

Of course, order volumes or frequencies can be increased without anything nefarious taking place, but suspicious activity, such as a sudden five-fold increase in order volume, or a new customer ordering more meds than any other customer, should be reported. Orders can still be shipped even if activity is reported. More info on reporting can be found here under the Reporting menu.

Other report criteria and due diligence

Distributors are required to make good faith inquiries (per 21 CFR 1301.74) to determine if receivers can possess controlled substances. He said that it’s also a good idea to keep a copy (hard copy or electronic) of downstream partners’ DEA registration. 

Cases of theft or loss of controlled substances must also be reported to the DEA. These reports can be filed electronically at the DEA’s Diversion Control Division site.

Pharmaceutical Innovations Report
Discover the latest breakthrough packaging technologies shaping the pharmaceutical sector. This report dives into cutting-edge innovations, from smart containers that enhance patient safety to eco-friendly materials poised to transform the industry’s sustainability practices. All from PACK EXPO. Learn how forward-thinking strategies are driving efficiency and redefining what’s possible in pharma packaging.
Learn More
Pharmaceutical Innovations Report
FDA warning letters surge - is your team prepared?
New guide reveals expert strategies to prevent regulatory issues and respond effectively to FDA enforcement actions in pharmaceutical and medical device manufacturing.
Read More
FDA warning letters surge - is your team prepared?